Literature DB >> 15377484

Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.

Takahiro Tamura1, Taizo Tasaka, Miharu Fujimoto, Yoshiko Matsuhashi, Tetsuya Fukumot, Shohei Mano, Minoru Kuwajima, Masami Nagai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15377484

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas.

Authors:  Boaz Karmazyn; Mervyn D Cohen; Samuel Gregory Jennings; Kent A Robertson
Journal:  Pediatr Radiol       Date:  2012-06-22

Review 2.  Hematologic toxicities of small molecule tyrosine kinase inhibitors.

Authors:  Nicholas A Barber; Wais Afzal; Mojtaba Akhtari
Journal:  Target Oncol       Date:  2011-11-30       Impact factor: 4.493

3.  Imatimid-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases.

Authors:  D Vanel; S Bonvalot; C Le Pechoux; A Cioffi; J Domont; A Le Cesne
Journal:  Skeletal Radiol       Date:  2007-06-23       Impact factor: 2.199

4.  Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia.

Authors:  Neetu Pandey; Geeta Yadav; Rashmi Kushwaha; Shailendra Prasad Verma; Uma Shankar Singh; Ashutosh Kumar; Prabhaker Mishra
Journal:  Adv Hematol       Date:  2019-01-01

5.  Bone marrow necrosis secondary to metastatic adenocarcinoma revealed by 18F-FDG PET/CT: A clinical case report.

Authors:  Ping Dong; Rong Tian; Lin Li; Minggang Su
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.